Sustained reductions in migraine days, moderate-to-severe headache days and days with acute medication use for HFEM and CM patients taking fremanezumab: Post-hoc analyses from phase 2 trials

Fremanezumab for the Preventive Treatment of Chronic Migraine

(2017) Stephen D. Silberstein et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study

(2015) Marcelo E Bigal et al.   LANCET NEUROLOGY

Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study

(2015) Marcelo E Bigal et al.   LANCET NEUROLOGY

Placebo Effects in Medicine

(2015) Ted J. Kaptchuk et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tolerance and Loss of Beneficial Effect During Migraine Prophylaxis: Clinical Considerations

(2011) Elizabeth W. Loder et al.   HEADACHE

Tolerance to the Beneficial Effects of Prophylactic Migraine Drugs: A Systematic Review of Causes and Mechanisms

(2011) Paul Rizzoli et al.   HEADACHE